Close Menu

mergers & acquisitions

Varian's Q1 revenues dipped 3 percent due to lower sales volume and lower average selling prices of certain analytical instruments products, the firm said.

A private equity firm has purchased Hycor, which was not a strategic fit for Agilent's operations.

Medco's decision to buy DNA Direct signals its intent to be a "one-stop shop" for payors and employers interested in using genetically guided medicine to make healthcare more efficient and lower costs.

Finnzymes had $20 million in revenues in 2009 and makes reagents, consumables, kits, and instruments for molecular biology applications.

Galapagos expects its drug discovery services operations to bring in around €70 million in 2010 revenues.

Danaher has closed the acquisition, and the mass spec operations will operate under the name AB Sciex. MDS plans to return the majority of proceeds from the sale to shareholders through a share buyback.

The firms have yet to receive US regualtory approval for their merger.

The FTC provided provisional approval of Danaher's purchase of MDS Analytical Technologies. However, it is requiring MDS to sell its laser microdissection business to Life Technologies to alleviate the agency's competition concerns.

The Canadian proteomics company bought the unit to strengthen its position in the biomarker services market.

The sales of certain gas chromatography product lines will satisfy the conditions for clearance of the acquisition in the EU.


GenomeWeb reports that Veritas Genetics is suspending its US operations.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.